Sreelakshmi24’s Blog

where life is all about learning

Posts Tagged ‘Cardiology

Pediatric Cardiac Specialists of Apollo Children’s Hospital perform a complicated intracardiac repair of complete A-V canal defect on a Nigerian infant

with one comment

The Pediatric Cardiac team at the new Apollo Children’s Hospital successfully performed a complicated surgery to treat a condition called complete a-v canal defect in a 4–month old Nigerian baby.

Speaking at the press briefing alongside the patient, Dr. Neville Solomon, Pediatric Cardiac Surgeon & Dr. Muthukumaran, Pediatric Cardiologist said, “The Nigerian baby was ailing with a condition called complete a-v canal defect. This consists of two holes in the heart with mitral and tricuspid valves possibly leaky as well. The child also has Down’s syndrome, which makes the surgery even more risky. The child was investigated by 2D echo, 3D echo and catheterization and angiogram. The surgery involved closing of the holes in the heart and repairing the mitral and tricuspid valves.”

The preoperative 3D echo was done by Dr. Muthukumaran, who is among the few cardiologists in the country trained to perform this investigative procedure. This 3D transesophageal echo at Apollo is the first of its type in Tamil Nadu. Dr. Neville Solomon added, “It is gratifying that the baby was brought in for surgery by the 4th month as usually beyond 6 months, the results are not as good. It is gratifying that the baby is doing well and will be returning home tomorrow. We have been treating numerous international patients at the hospital”

Addressing the gathered media, Dr. Prathap C Reddy, Chairman, Apollo Hospitals Group said, “This 80- bedded Apollo Children’s Hospital is emblematic of the change we wanted to see in child healthcare, and an extension of our long and successful foray in quality pediatrics. Every little life represents immense potential and the onus is on us to nurture it.”

Ms. Preetha Reddy added, “True to the Apollo way, we have not stopped with the best of technology and expertise. A lot of thought has gone into making the process of healing as child-friendly as possible. The ambience, the mood, the culture have all been shaped around the young patient. I hope PAWS, the latest member of the Apollo family, will steal the day. PAWS, our mascot at the Apollo Children’s Hospital, is a teddy bear that will be there to welcome the young patients, and spread the cheer during their stay at the hospital.”

Situated in the close vicinity of flagship Apollo Hospitals at Greams Road, The Apollo Children’s Hospital is one of the finest in the country. Complete with an NICU, Isolation ward, three operation theatres, sunshine ward, cheerful private rooms and tasteful suites, the new hospital leaves no stone unturned in providing the best pediatric care.

The cardiology team consisting of Pediatric Interventional Cardiologist and the Cardio Thoracic Surgeon are available to tackle highly complicated congenital anomalies and the Pediatric Cardiac Intensive Care Unit looks after these cases pre and post operatively. The department of Pediatric Surgery and Pediatric Urology carries out various procedures on children and neonates including laparoscopic surgery. The other super specialties are Pediatric Neurology-Neuro Surgery Nephrology and Gastroenterology, which are well covered by expert consultants for an accurate diagnosis and proper treatment.

The department of Haemato Oncology gives a new lease of life to the hitherto fatal disease like A –plastic anemia, Leukemia and Storage disorders etc., Bone marrow transplants have been done on many children with excellent results. The Neonatal Intensive Care Unit with expert neonatologists take care of premature babies with very low birth weight with good out come comparable to international standards.

Equipped for every paediatric emergency, Apollo Children’s Hospital is geared to care for acute problems and emergencies promptly and efficiently in the “golden hours” for all the emergencies. The emergency and Pediatric Intensive Care Unit (PICU) will be complementary to each other will sole aim to save the precious lives and is functional 24X7. The transport unit consisting of attained registrar level pediatrician, well-trained nurses and paramedical staff are ready to rush to the site of emergencies to pick up the sick babies at Airport, home or even from any other hospitals. They will assess the sick child, stabilize the child and transport the child to our children’s hospital. The doctors, nurses and paramedical staff are well trained in the pre hospital care of these patients. For the sick newborn state of the art Transport Incubators are available for their safety. The PICU is unique as it is headed by the Senior Consultants well trained in delivery of intensive care.

Written by sreelakshmi

4 July, 2009 at 6:24 am

Increased use of NT-proBNP could help curb India’s heart disease toll

leave a comment »

International Consensus Statement calls for routine screening for at-risk patients

The biomarker, NT-proBNP should be widely used in
both primary care, as well as the emergency department, to more accurately diagnose patients with heart failure, claims Dr Antoni Bayes-Genis, a renowned cardiologist from Barcelona, Spain. Indian cardiologists will hear first hand from Dr Bayes-Genis, who is also one of the authors of the International Consensus Statement on the use of NT-proBNP in the management of heart failure – an important issue given India will have the highest number of heart failure patients in the world by 2015.

The international panel of experts, including Dr. Bayes-Genis, Director of Heart Failure and Heart Transplant Unit in Hospital de la Santa Creu i Sant Pau. Barcelona, recently released a set of recommendations on the use of NT-proBNP. These recommendations, which are being discussed in India by Dr. Bayes-Genis, were published in the American Journal of Cardiology. The panel concluded that NT-proBNP holds great promise as a routine screening tool in high risk populations, as well as a useful screening tool in the general population for detection of cardiac abnormalities and the prediction of future cardiovascular events, such as heart failure.

“By routinely testing people at-risk of developing heart disease for levels of NT-proBNP, doctors are able to diagnose the condition earlier and more accurately, which can have a significant impact on the long term health outcomes of patients. It enables the detection of even early stages of heart failure, a time in the disease process where there are generally no obvious symptoms”, said Dr. Bayes-Genis.

NT-proBNP is an inactive protein with a long half-life, thus it is more stable,, and remains in the blood stream longer than other markers., This makes NT-proBNP a more sensitive test for use in the early detection and management of congestive heart failure.

Cardiovascular disease, including heart failure, is still the single most common cause of death worldwide. Unlike many conditions, heart failure is expected to continue to rise, due to ageing populations, the adoption of increasingly Westernised lifestyles and increased survival after other cardiovascular events. The incidence of heart failure in India is growing at a rate of 1.57million cases each year.

“Indians are more susceptible to heart failure, due to genetic pre-disposition as well as changes in dietary habits and lack of physical exercise. The NT-proBNP test can assist in the early diagnosis of heart failure which could reduce the incidence in the country,” said Dr Bhuwnesh Agrawal, Managing Director and Chairman of Roche Diagnostics, India.

As heart failure is a degenerative condition, it is not reversible and therefore an early and accurate diagnosis is crucial to ensure positive healthcare outcomes for patients. However, the condition is difficult to diagnose as early symptoms are non-specific and similar to those observed in many pulmonary disorders. As many as 50% of patients referred to cardiologists by general practitioners are initially misdiagnosed.

“The understanding of heart failure is still relatively low both among the public and healthcare professionals,” said Dr Bayes-Genis. “Yet early and accurate diagnosis can significantly impact treatment outcomes, and could moderate or even halt disease progression. Therefore it is important to fully utilise NT-proBNP and incorporate it into routine screening for at-risk patients. As NT-proBNP can detect even mild and moderate stages of the disease, it has been proven to be the most reliable and accurate marker to diagnose and assess a person’s risk of heart failure.”

NT-proBNP was approved by the US Food and Drug Administration (FDA) as an objective marker for the diagnosis and prognosis of heart failure as well as the risk assessment in patients with acute coronary syndrome. It also offers strong prognostic value to help assess the increased risk of cardiovascular events and mortality in patients with stable coronary artery disease.

In addition to its diagnostic and prognostic capabilities, NT-proBNP is being evaluated to guide treatment, to ensure patients receive the appropriate form and level of treatment, reducing cardiovascular event and ultimately improving patient management.

The potential benefit of regular NT-proBNP screening is particularly significant for at-risk population groups. High-risk patient groups include people suffering from diabetes, high cholesterol, high blood pressure, known coronary artery disease, or those aged 60 years and older among others.

“Regular screening of at-risk patients’ NT-proBNP levels can not only help save lives, but will also significantly reduce the patient’s cost burden. Medical and lifestyle interventions can be very effective treatment options for mild- to moderate heart failure. However, it is crucial that they are started early as the damage done to the heart in the severe stages of the disease is irreversible and ultimately fatal,” concluded Dr Bayes-Genis.

References for the article:

  1. Januzzi, JL. Comments from the International NT-proBNP Consensus Panel. Presented at: proCardio Symposium, Baveno, Italy. 2008.
  2. Mair, J. et al. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clinical Chemistry & Laboratory Medicine 2001; 39: 571-588.
  3. Ordonez-Llanos, J. NT-proBNP: Analutical Considerations. In: NT-proBNP as a biomarker in cardiovascular diseases. Eds: Bayes-Genis, A. and Januzzi, JL. Thomson Reuters, 2008.
  4. Elin, RJ. et al. Laboratory and clinical aspects of B-type natriuretic peptides. Archives of Pathology and Laboratory Medicine 2004; 128: 697-699.
  5. Pemberton, CJ. et al. Deconvolution analysis of cardiac natriuetic peptides during acute volume overload. Hypertension 2000; 36: 355-359.
  6. World Health Organisation. The Atlas of Heart Disease and Stroke. 2004. Accessed on 3 October 2008 at: http://www.who.int/cardiovascular_diseases/resources/atlas/en/
  7. Joint scientific symposium of ICMR and university of Minesota
  8. National Heart, Lung, and Blood Institute. National Institutes of Health Data Fact Sheet: Congestive Heart Failure. September 1996.
  9. Roche Diagnostics. Data on File 2002.
  10. Roche Diagnostics. Elecsys proBNP – A novel approach for the management of heart failure.

    Piramal Healthcare honours the best interventional cardiologists in India

    with 2 comments

    Piramal Healthcare Limited, one of India’s largest pharmaceutical companies, awarded the ‘Piramal Knowledge Academy Best Intervention Award 2009‘ to four eminent interventional cardiologists at the National Intervention Council (NIC) on April 26, 2009 in Hyderabad. Around 500 interventional cardiologists attended the program. Dr. Sarat Chandra, Chairman, National Intervention Council was instrumental in integrating this award in NIC. He presided over the conference and headed the jury that chose the winners.

    Piramal Knowledge Academy supports the cause of the Percutaneous Transluminal Coronary Angioplasty (PTCA) Registry and is aimed at promoting unique Percutaneous Coronary Intervention (PCI) by interventional cardiologists. PTCA Registry is a mid-term scientific fiesta which is organised every year, where more than 100 pre-selected cases are shown and discussed for everyone’s benefit over the course of the three days of the Registry. Piramal Knowledge Academy will continue to honour and acknowledge the best angioplasty cases in the country every year.

    Piramal Knowledge Academy conducts a host of Advisory Panel Programmes, Skill Upgradation Programmes and Collaborative Educational Programmes with the medical fraternity. Dr. Swati Piramal, Director Communications & Strategic Alliances, Piramal Healthcare Limited said, “Piramal Knowledge Academy was conceptualized with the belief that sharing of knowledge with the medical fraternity is an imperative to alleviate the lives of the end patients and thereby the status of healthcare in India. It is our humble attempt at recognizing and felicitating stellar achievements in interventional cardiology.”

    The winners of the prestigious award this year are:

    • Dr. Navneet Singh from AIIMS, Delhi for his unusual case of CoArc dilatation,
    • Dr. Bhanu from J.J. Medical College, Mumbai for her case on ballooning and stenting in peripheral and pulmonary artery stenosis,
    • Dr. Pankaj Jariwalla from Nizam’s Institute of Medical Sciences, Hyderabad for his case on left systemic artery to pulmonary vein AV valve formation, closed by vascular plug & coil embolisation and
    • Dr. Harikrishna from Shri Chitra Institute of Medical Sciences, Trivandrum for Ductal stenting in a neonate. The winners were honoured with a monetary award of Rs. 20,000, a certificate and an annual print subscription to an international health journal of repute.

    The medical fraternity unreservedly appreciated this initiative from Piramal Healthcare. “It is a great honour for me to receive this award,” said Dr. Harikrishnan.